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Medical Device Innovation:
Prospective Solutions for an Ecosystem in Crisis
Adding a Professional Society Perspective
Mitchell W. Krucoff, MD,* Ralph G. Brindis, MD, MPH,† Patricia K. Hodgson, BA,*
Michael J. Mack, MD,‡ David R. Holmes, JR, MD§
Durham, North Carolina; San Francisco, California; Dallas, Texas; and Rochester, Minnesota
Barriers to medical device innovation compromise timelines and costs from bench to bedside. Frag-
mented strategies by individual competitors are no longer sustainable. Pragmatically focused pre-com-
petitive collaboration across stakeholders approaches innovation as an ecosystem. Desiloing experience
and expertise encourages high-impact infrastructure efﬁciencies unique to pre-competitive constructs.
Alignment of processes and objectives across the regulatory, reimbursement, clinical research, and clin-
ical practice enterprises, with particular attention to the total product life cycle and continuous accrual
of safety information, promotes more predictable equipoise for speed of access relative to residual
safety concerns. Professional societies are well positioned to convene pre-competitive dialogue, facili-
tate alignment, and add perspective to equipoise within the innovation ecosystem. (J Am Coll Cardiol
Intv 2012;5:790–6) © 2012 by the American College of Cardiology FoundationNovel cardiovascular devices have been associated
with improved patient outcomes for increasingly
large populations while ongoing innovation con-
tinues in response to unmet needs for a broad array
of disorders. Especially in the United States, how-
ever, device innovation has been impeded by a
number of contemporary barriers. Among these
barriers are constrained financial resources, rising
See page 797
research costs, concerns with predictability of reg-
ulatory processes, as well as several important
advances in medicine that have had unanticipated
effects on innovation. We propose specific avenues
where alignment and leveraging of professional soci-
From the *Duke University Medical Center/Duke Clinical Research
Institute, Durham, North Carolina; †Institute of Health Policy Studies,
University of California, San Francisco, California; ‡Baylor Heart
Hospital, Dallas, Texas; and the §Mayo Clinic, Rochester, Minnesota.
The authors have reported that they have no relationships relevant to the
contents of this paper to disclose. Dean Kereiakes, MD, served as Guest
Editor for this paper.Manuscript received November 3, 2011; revised manuscript received
March 22, 2012, accepted March 22, 2012.ety and federal agency resources could provide unique
efficiencies, enhance predictability of equipoise be-
tween speed of innovation and safety concerns, and
promote processes that actively incentivize both in-
novation and ongoing accrual of safety information.
Regulatory Efforts to Facilitate
Medical Device Innovation
There have been several initiatives to streamline the
process of regulatory approval of drugs and devices.
• The combination of rising research and development
costs and reduced drug and device approvals in the
United States between 1994 and 2004 led the U.S.
Food and Drug Administration (FDA) to launch
the Critical Path program (1), which focused on
inadequacies of the clinical research enterprise that
impede new therapy development.
• During this time, international regulatory agen-
cies in the Global Harmonization Task Force,
jointly with industry, sought to focus regulatory
device evaluations on essential principles of safety
and performance (2).
• In 1997, the FDA Modernization Act codified
the construct of “least burdensome” approaches
•l
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791to medical device evaluation, including dialogue with
FDA review teams early in planning for investigational
device exemption (IDE) clinical trials, or “pre-IDE
dialogue.”
In 2010, the FDA Center for Devices and Radiologic
Health launched the Medical Device Innovation Initia-
tive to facilitate speed to market of transformative tech-
nologies (3).
Despite these efforts, medical device innovation, particu-
arly in the United States, has reached a crisis stage.
idespread concerns include late bedside access to impor-
ant technologies in the United States (“device lag”) and a
hift in industry research and development priorities to
arkets outside the United States due to cost and regulatory
nd infrastructure barriers (“industry exodus”).
Conversely, there are those who criticize medical device
egulations as too lax and propose raising the threshold of
re-market evidence (4,5). This view has been amplified by
ecent safety issues that were not identified by pre-market
tudies, such as drug-eluting stent thrombosis and failures
f pacemaker leads and implantable defibrillators.
These divergent views point to the critical issue: the lack
f a consistent approach that balances the pace of medical
evice innovation with sufficient safety data relevant to real-world
linical practice. The absence of transparent, predictable pro-
esses for establishing equipoise around how fast is fast
nough, how safe is safe enough, and for specific new device
echnologies leads instead to confusion, risk aversion, re-
undancy, and delays contrary to the best interests of
dvancing the public health.
Concern regarding the adequacy of the current 510(k)
egulatory processes was recently the subject of an Institute
f Medicine report, which concluded that the 510(k)
rocess, through which most devices are approved, “lacks
he statutory basis to make it a reliable screen of safety and
ffectiveness . . . as long as the standard for clearance is
ubstantial equivalence to any previously cleared device” (6).
efining “innovation” as “improving the quality of, effi-
iency of, or access to health care,” the committee contin-
ed: “the 510(k) process was not designed to reward . . . or
ncourage innovation” although it is “generally more eco-
omical, faster, and less burdensome than the PMA [pre-
arket approval] process for both industry and the FDA.”
Stakeholders in medical device innovation include
atients, medical practitioners, professional societies, re-
earchers, research organizations, device manufacturers,
he investment community, hospitals and healthcare orga-
izations, insurers, federal regulatory and reimbursement
gencies, and the U.S. Congress, which passes the legisla-
ion governing and funding those agencies. Perspectives
ary from the bedside to federal agencies to the economic
rivers of the medical industry. Such different perspectives
ake simple questions such as “how safe is safe enough,”how fast is fast enough,” and what really is the “cost of
elay” seem unsolvable.
Important recent advances in the United States include
etter clinical outcomes and improved safety reporting.
oth have affected device innovation, requiring larger trials
o show benefit and creating a generally risk-averse envi-
onment. Other landscape changes affecting time and ex-
ense associated with device innovation in the United States
nclude eventuation of comprehensive protection of elec-
ronic health information, meticulous standards for coding
nd billing for healthcare services, and the maturation of
ardiovascular device markets outside the United States,
nabling them to contribute high-quality research data.
To revitalize device innovation, we must first recognize
hat it is a highly interconnected “ecosystem,” wherein
egulatory and reimbursement processes, clinical trial infra-
tructure, public expectations, and investment decisions
ynamically interact. To address the full spectrum of chal-
enges will require frank communication among all stake-
olders. Professional societies
re well positioned to help or-
hestrate a neutral ground for
uch dialogue, as well as to help
ultivate a collaborative, pre-
ompetitive focus on the most
ritical barriers with a pragmatic
mphasis on working together to
reate both short- and long-term
olutions.
afety Concerns,
esidual Risk, and the
ost of Delay
Safety concerns are the primary
counterpoint to the pace of device innovation. Improve-
ments in safety reporting, however, have not been balanced
with management of clinical, commercial, public, media,
and medicolegal concerns surrounding safety events. The
value of improved safety reporting may be undermined if it
creates a risk-averse atmosphere that impedes important
further innovation.
Considerable work needs to be done to transform both
key processes and perception to address medical device
safety as a continuum. The U.S. legislatively mandated
“reasonable assurance of safety” is frequently misinterpreted
as meaning that approved devices are absolutely safe. Ex-
pectations must be clarified that no device is perfectly safe
(7) and that rarer or longer term safety unknowns must be
progressively uncovered with rigor in both the pre- and
post-market. The international regulatory construct of “re-
sidual risk” assessment (8,9), where any level of defined
device benefit is balanced with any still-undefined safety
Abbreviations
and Acronyms
CMS  Center for Medicare
and Medicaid Services
CSRC  Cardiac Safety
Research Consortium
EHR  electronic health
records
FDA  Food and Drug
Administration
IDE  investigational device
exemption
NCDR  National
Cardiovascular Data Registryconcerns, provides a fertile and practical focus for aligning
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792regulatory milestones, reimbursement decisions, statistical
models, public expectations, and business models over the
total product life cycle.
To define the boundaries of residual risk, computer
simulations, pre-clinical bench testing, and animal mod-
els may be informative to clinical trial designs (10,11).
Continuity of safety information accrual across pre- and
post-market human trials aligns well with statistical
approaches, including the FDA’s recent guidance on
Bayesian methods for device applications (12). As a
continuum, residual risk unresolved by pre-market randomized
trials should provide the basis for suitable post-market studies
(13), rather than impeding device approval and bedside
access per se.
Residual risk as a continuum could reach further through
the innovation ecosystem to align approval decisions with
public perception and reimbursement decisions. If a device
of great clinical benefit has only short-term, but reasonable
safety information, conditional status of approval aligned
with limited reimbursement might facilitate the speed of
access while informing the public of an exciting new
technology with both great potential and significant un-
knowns. As subsequent post-market registries, global trials,
or other high-quality data reduce confidence intervals
around rare safety events and provide longer term outcome
data, a more unconditional approval status could be awarded
in parallel with pre-determined decisions to increase reim-
bursement, all aligned with greater public reassurance of
device safety. This kind of multisector alignment along the
lines of accrual of safety information would incentivize,
rather than impede, innovation.
The “cost of delay” is often excluded from the balance
between speed of innovation and the need for adequate
safety information (14). Established models for the financial
impact of delays on revenues do not include clinical calcu-
lation of lives lost, rehospitalizations, and other morbidities
related to delayed access to better technology. With growing
quality of human data from outside the United States, for
selected high-impact devices, statistically robust assessments
of the clinical cost of delay may importantly add to the
determination of equipoise for “reasonable” assurance of
safety and effectiveness approval decisions. Integration of
the clinical cost of delayed access into a more comprehensive
calculus of the continuum of residual risk for approval
decisions represents an important potential by-product from
the advance of high-quality global research efforts.
Safety as a continuum and the accrual of data informing
residual risk assessment crystallizes 3 central directions to
revitalize medical device innovation: 1) predictable determi-
nation of equipoise between speed of innovation and resid-
ual safety concerns; 2) promoting efficient operational re-
search infrastructure supporting item 1; and 3) orchestration
of ongoing, collaborative pre-competitive dialogue. Weaddress 5 potential solutions along these lines as listed in
Table 1.
Potential Directions and Solutions
Professional society involvement: education; perspective;
and collaboration. Professional societies have advanced the
eld of medicine with the development of practice guide-
ines, quality metrics, and electronic data capture of quality
egistries. Examples of interactions supporting federal agen-
ies with professional society electronic data capture systems
nclude the use of the ACC-NCDR (American College of
ardiology National Cardiovascular Data Registry) infra-
tructure to support the Center for Medicare and Medicaid
ervices’ (CMS) continuing evidence decision on implant-
ble defibrillators, and the current interaction between
DA, CMS, ACC-NCDR, and the Society of Thoracic
urgeons’ Adult Cardiac Database for the Transcatheter
alve Therapy Registry. To date these activities have
ocused exclusively on post-market practice of medi-
ine—on guidelines, not on guidance documents.
As the key repositories of physician specialists, profes-
ional societies must expand physician focus and education
nto pre-market regulatory and reimbursement issues to
omplement such post-market interests. The bedside per-
pectives of unmet needs, therapeutic options, patient ad-
ocacy, and equipoise in risk versus benefit concerns are
ritical to reasonable determination of safety and benefit
quipoise for pre-market pivotal clinical trial objectives and,
ence, to the predictability of approval for any particular
evice. Additionally, more widespread insight into the early
tages of device evaluation would enhance physician-patient
nteractions, such as informed consent for procedures and
anagement of patient and public expectations for specific
evice safety issues.
Well-informed physicians could enhance pre-IDE dia-
ogue by helping regulators and manufacturers find common
round and equipoise. One unanticipated consequence of
ery early pre-IDE meetings between industry and regula-
ory has been to marginalize the role of the clinician outside
f a handful of clinical trialists (15). Without academic
linician involvement, the positions of regulators and indus-
ry tend to become contentious. The determination of what
s “reasonable” assurance of safety and effectiveness—
ncluding endpoint selection, statistical confidence, compar-
tors—ultimately centers on the question of risk and ben-
Table 1. 5 Directions for the Future of Device Innovation
1. Better integration of professional societies and clinical perspectives
2. Alignment with regulatory requirements
3. Alignment with reimbursement processes
4. Alignment of clinical practice and clinical research data5. Globalization of new device evaluation
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793efit. Knowledgeable physician involvement, from the most
basic, pre-competitive issues related to disease states to the
details of specific procedures and devices could shift this
dialogue from contentious to collaborative. Professional
societies must encourage and educate physician members to
support interactions with federal agencies and medical
industry, either as selected experts or in transparent expert
panels.
Beyond educating their own membership, professional
societies could also provide a convening function to facilitate
pre-competitive dialogue. These societies have frequent
contact with the manufacturing industry and federal regu-
latory and reimbursement authorities, and through their
members, direct contact with patients and hospitals
throughout the United States. Societies also have estab-
lished experience with program planning and transparency.
Beyond education and convening, unique and already
operational professional society resources could be leveraged
on behalf of other areas currently creating barriers to
innovation in the United States, particularly the high cost
and slow enrollment typifying U.S. research sites. Regis-
tries, such as the ACC-NCDR and Society of Thoracic
Surgeons’ databases constitute continuous electronic data
streams funded by clinical revenues, and institution of
enhanced quality control measures has resulted in more
reliable data. With only modest augmentation, such na-
tional electronic infrastructure could be leveraged for pre- or
post-market randomized trials or registries, providing uni-
form terminology and definitions across studies while con-
comitantly increasing the speed and reducing the cost of
dedicated research activities.
Greater professional society attention and involvement
could help revitalize the innovation ecosystem, facilitate
more informed and transparent dialogue around central
questions, such as safety equipoise, and leverage infrastruc-
ture efficiencies to streamline trial processes. However, there
are potential pitfalls to be avoided in endorsing this ap-
proach. Traditionally, societies have not been structured to
coordinate multilevel long-term collaborations that include
both industry and federal agencies, and society-driven da-
tabases have not been sufficiently granular to address specific
device safety concerns. Even more importantly, the role of
professional societies must be carefully structured to avoid
creating new barriers or adding further complexity or
inefficiencies. Thus, although such societies formally en-
dorse best practice guidelines and govern the processes that
produce them, it would be neither desirable nor appropriate
to require such endorsement of approval decisions per se.
Alignment with regulatory processes and objectives. Pivotal
DE trials that promote device approval, clinical benefit
ata that support reimbursement decisions, and clinical
rials that drive best practice guidelines are often conceived
nd executed independently. It would be far more efficient
nd at least as informative to integrate these objectives usingcommon operational infrastructure and align studies
equentially over the total product life cycle (Fig. 1) to
ccrue residual risk data. In this way, suitable prospective
se of randomized and registry study designs could predict-
bly and adaptively provide pre- and post-market data
uited to any specific device needs for approval, reimburse-
ent, and market uptake via clinical adoption.
Another benefit of alignment with the regulatory total
roduct life cycle framework is the natural potential of
ngoing dialogue about process improvement. Shared glob-
lly, professional society facilitated perspectives could be-
ome more informed as to how different international
egulations influence both speed of access and degrees of
afety uncertainties (16). The Institute of Medicine has
ecommended that the FDA formalize such a quality
ssurance initiative, including comparisons with interna-
ional regulatory decisions (6).
A useful example of collaboration along these lines is the
ardiac Safety Research Consortium (CSRC), a public-
rivate partnership developed under the FDA’s Critical
ath Program (17). Through think-tank meetings, the
SRC addresses scenarios where rare but catastrophic
ardiac safety concerns create barriers to innovation. The
SRC then produces both white papers and research
rojects promoting collaborative pre-competitive solutions.
rograms to date include drug-device safety interactions,
uch as dual antiplatelet therapy and drug-eluting stent
hrombosis, the safety of atrial fibrillation ablation, the
mpact of vascular access on antithrombotic bleeding risk,
Figure 1. The Total Product Life Cycle Approach to Medical Device
Development and Regulation
Medical device development is an iterative process that rapidly incorpo-
rates pre-clinical, clinical, and manufacturing experience into next-genera-
tion concept and design. Reprinted, with permission, from the U.S. Food
and Drug Administration, CDRH Innovation Initiative White Paper. Available at:
http://www.fda.gov/downloads/AboutFDA/CentersOfﬁces/CDRH/CDRH
Innovation/UCM242528.PDF.
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794and electrocardiographic technologies detecting drug-
induced corrected QT-interval prolongation (18,19).
Alignment of CMS processes. Reimbursement decisions are
critical to all phases of new device innovation. Ambiguities
in decisions on reimbursement for Category B investiga-
tional devices have direct impact on site-based participation
in clinical trials, as hospitals are poorly resourced to absorb
nonreimbursed expenses. Post-approval reimbursement de-
cisions affect clinical adoption rates, as well as manufacturer
revenues. Disconnects between pre- and post-market ap-
proval milestones and reimbursement decisions thus affect
both data accrual and revenues that foster further innova-
tion. In the United States, the FDA and the Center for
Medicare and Medicaid Services operate in relative isolation
both in their processes and in the objectives of data
collection to show reasonable assurance of safety and effec-
tiveness or metrics of clinical benefit, respectively.
Aligning processes and designing trials informative to
both FDA and CMS could lower research and development
costs and accelerate timelines for new devices. In September
2010 in the Federal Register, parallel review for new devices
ere announced (20). This step represents an opportunity
nd a paradigm to bridge federal agencies into a more
fficient and predictable system of approval and reimburse-
ent while preserving their independent jurisdictions.
Examples of CMS and professional society alignment
nclude continuing evidence or “pay for data” decisions for
efibrillators and, most recently, for percutaneous aortic
alves (1,21). A unique feature of the national coverage
ecision for valves includes the expansion of coverage if the
DA’s approved indications are extended over time—
nother example of efficiencies through alignment. For
ontinuing evidence, mandatory data entry into NCDR
egistries provides an integrated data platform supporting
tilization and device safety assessments, including longer-
erm follow-up in older patients through linkage to the
edicare database. Recent enhancements in monitoring
nd auditing of data entry continue to improve data quality.
s the value of further improvements is more widely appreci-
ted through educational programs and peer-review publica-
ions, the stage is set to support new policies for incremental
eimbursement aligned with accrual of residual risk informa-
ion throughout the total product life cycle. Where today safety
ata are the most notable barrier in the device ecosystem, such
lignment could create incentivized safety data accrual and
ould, literally, incentivize innovation.
Align clinical and research infrastructures. Historically, the
linical care and clinical research enterprises have been separate
ntities. Although research requires meticulous attention to in-
ormed consent, information privacy, and protocol-related
etails, a completely separate research infrastructure is
edundant. Statistical modeling to include more real-
orld populations in device trials is an important stepoward narrowing the gap between studied patients and eeal-world practice (22,23). Beyond statistical models,
owever, it is critical for the clinical and research enter-
rises to converge at an operational level.
Electronic data capture tools may enable such conver-
ence at the site level. Historically, electronic databases have
erved administrative, quality reporting, and oversight roles.
hese databases include the Medicare database; the New
ork, Washington, and Massachusetts state databases; and
he Swedish national SCAAR (Swedish Coronary Angiog-
aphy and Angioplasty Registry) database. These and other
ongitudinal clinical databases have provided observational
ata on stent thrombosis and femoral closure devices useful
or both regulatory and practice guidelines purposes.
Electronic information capture, particularly health re-
ords (EHR) and quality registries, provides a single point
f data entry for both clinical and research purposes. The
DA’s Sentinel Initiative, launched in May 2008, is a
ritical Path collaboration with academic groups to develop
a proactive system that will complement existing systems
hat the Agency has in place to track reports of adverse
vents linked to the use of its regulated products” (24) using
HR from millions of patients. Using the Veterans Admin-
stration Medical Centers EHR, a bidirectional query sys-
em for FDA safety concerns is in place via the CART CL
Cardiovascular Assessment, Reporting and Tracking for
ath Labs) database (25,26).
The ACC-NCDR includes a portfolio of registries for
cute coronary syndromes, cardiac catheterization and per-
utaneous coronary intervention, implantable defibrillators,
arotid artery revascularization, and pediatric and congenital
eart disease. These registries are procedural and episodic
are-based, but they can readily be merged with longer term
ata, such as Medicare, to mine outcomes, such as mortal-
ty, rehospitalizations, myocardial infarctions, as well as
harmaceutical and cost data; the result is rich clinical
nformation in cohorts far larger than any clinical trial at a
raction of the cost (27). The Society of Thoracic Surgery
STS) Adult Cardiac Surgery Database has recently been
uccessfully linked to the SSDMF (Social Security Death
aster File). The STS and ACC-NCDR databases have
een linked to each other as well as to the SSDMF and
MS administrative databases to compare intermediate-
erm outcomes for coronary revascularization in the AS-
ERT (ACCF-STS Database Collaboration on the Com-
arative Effectiveness of Revascularization Strategies) trial.
n another example, the SAFE-PCI for Women (Study of
ccess Site for Enhancement of PCI for Women) trial (28)
as used the National Cardiovascular Research Initiative to
mport data directly from the NCDR Cath-PCI registry
nto a prospective, randomized trial of vascular access in
omen. Such direct data linkage from already active NCDR
ites saves 60% of study coordinator work per patient
nrolled.
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795Another efficiency in using such centralized infrastructure
is the de facto application of consistent nomenclature and
definitions for descriptors, results, and outcomes. Such
consensus definitions have particular value for the accrual of
safety information, as has been exampled by the use of the
Academic Research Consortium (29) stent thrombosis def-
initions and the integration of the Academic Research
Consortium valve definitions into the ACC-STS TVT
registry.
Involve the global cardiovascular community. Much atten-
ion has been directed to the “exodus” of medical device
esearch and manufacturing from the United States and to
he late arrival of devices for clinical practice in the United
tates. In part, this is due to the inefficiencies, rising costs,
nd dropping reimbursements that currently characterize
he U.S. arena and that urgently need to be addressed.
owever, it is important to recognize that this shift also
eflects the very positive advance of device research outside
f the United States, including the rising markets in India
nd Asia-Pacific. Global dissemination of good clinical
ractice standards and investigator education on protocol
ompliance now produces high-impact peer-review litera-
ure based on high-quality data. As regulatory authorities
ontinue to work on global convergence and harmonization
f device approval principles and processes, this shift also
ignals the very real potential of global device evaluation
trategies.
This advance mandates a new vision of how American
takeholders participate in the global cardiovascular com-
unity. Although selected nations may have more interest
n earlier device access despite greater risk and others have
ore interest in later access with lower residual risk, it seems
ikely that patients and doctors would support the emer-
ence of devices without undue hazard or delay as a matter
f optimal global public health (30). A global clinical view
f “how safe is safe enough” could be useful to regulatory
uthorities considering new device approvals in the context
f public health within their jurisdiction. Toward this end,
lobal manufacturing, international regulatory harmoniza-
ion, and collaborations around cardiovascular clinical re-
earch and surveillance are to be encouraged. Professional
ocieties are crucial to this international conversation.
onclusions
Many contemporary impediments to innovation actually
represent important advances in medicine and in health
care—in clinical outcomes, safety reporting, electronic in-
frastructure, and global research quality—that can encour-
age rather than impede cardiovascular device innovation.
Pre-competitive collaborations that foster efficiencies can
help offset the effect of more difficult barriers, such as
resource constraints. Such solutions, which remove redun-
dancy, integrate and align objectives of regulatory approval,reimbursement, and best clinical practice, are well suited in
the current era of economic fragility. Professional societies
are uniquely positioned to help facilitate such transforma-
tion and revitalize the medical device innovation ecosystem.
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